Drug Trial Radar · NCT03216759
Effects of Comprehensive Intestinal Protection Strategy on Postoperative Intestinal Complications
Last checked: Nov 19, 2026Latest source record: Jul 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
182
Planned (sponsor's estimate)
Start
Aug 2017
Primary completion
Oct 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 13, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the morbidity of intestinal injury after open surgery and observe the effect of comprehensive intestinal protection strategy on postoperative intestinal complications in patients undergoing laparotomy with general anesthesia.
Conditions
- Intestinal Complications
- Laparotomy
Interventions
Ischemic preconditioningProcedure
After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
DexmedetomidineDrug
At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
Patient-controlled epidural analgesiaProcedure
Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of digestive system complications after operationTime frame: 12 hours to one week after surgery
- The concentration of intestinal fatty acid-binding protein (I-FABP)Time frame: 12 h after operation
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.